Q-omics provides the consensus-scored ANKRD20A5P profile across patient tissues and cancer cell-line models. ANKRD20A5P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ANKRD20A5P is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, ANKRD20A5P RNA expression shows 18,079 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where ANKRD20A5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD20A5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD20A5P survival associations across molecular data types. ANKRD20A5P RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD20A5P RNA expression–survival associations across cancer types. High ANKRD20A5P expression shows unfavorable associations in MESO, LUAD, ACC and THCA, but favorable associations in BLCA and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for ANKRD20A5P RNA expression.
This table summarizes ANKRD20A5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD20A5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD20A5P shows lower tumor expression in HNSC and KICH and higher tumor expression in COAD, BRCA, CHOL and PAAD. The HNSC box plot shows higher ANKRD20A5P RNA expression in normal versus tumor tissue (log2 FC = −1.126, t-test p < 0.001).
This table shows molecular features associated with ANKRD20A5P in patient tissues and cancer cell lines. In patient samples, ANKRD20A5P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD20A5P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH.
